Search for Clinical Trial Results
Hyperplasia - 271 Studies Found
Status | Study |
Recruiting |
Study Name: Ultradian Subcutaneous Hydrocortisone Infusion in Addison Disease and Congenital Adrenal Hyperplasia Condition:
Date: 2013-11-28 Interventions:
|
Completed |
Study Name: Catecholamine Reserve and Exercise Tolerance in Healthy Volunteers and Patients With Congenital Adrenal Hyperplasia Condition:
Date: 2001-02-28 |
Completed |
Study Name: Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia Condition:
Date: 1999-11-03 Interventions:
|
Recruiting |
Study Name: Prenatal Dex Study Condition: Congenital Adrenal Hyperplasia Date: 2016-05-25 Interventions: Behavioral: Neuropsychological and cognitive assessment |
Completed |
Study Name: Congenital Adrenal Hyperplasia: Calcium Channels as Therapeutic Targets Condition: Congenital Adrenal Hyperplasia Date: 1999-11-03 Interventions: Drug: Nifedipine |
Recruiting |
Study Name: A Study of the Efficacy, Safety and Tolerability of Chronocort in Treating CAH Condition: Congenital Adrenal Hyperplasia Date: 2016-08-22 Interventions: Drug: Hydrocortisone Modified release hydrocortisone |
Completed |
Study Name: Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia Condition:
|
Completed |
Study Name: Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia Condition:
|
Active, not recruiting |
Study Name: A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease Condition: Multicentric Castleman's Disease Date: 2011-04-21 Interventions: Drug: Siltuximab Type=exact number, unit=mg/kg, number=11, form=intravenous solution, route=intravenous. |
Completed |
Study Name: A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman's Disease Who Demonstrated Benefit From Previous RoActemra/Actemra Treatment Condition: Castleman's Disease Date: 2010-08-13 Interventions: Drug: tocilizumab [RoActemra/Actemra] maintenance dose |